Bismuth Subcitrate Potassium / Metronidazole / Tetracycline Dosage
Medically reviewed by Drugs.com. Last updated on Sep 16, 2021.
Applies to the following strengths: 140 mg-125 mg-125 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Helicobacter pylori Infection
Bismuth subcitrate potassium 420 mg-metronidazole 375 mg-tetracycline 375 mg orally 4 times a day (after meals and at bedtime)
-Duration of therapy: 10 days
-Omeprazole 20 mg should be given orally 2 times a day during treatment (after morning and evening meals).
-Helicobacter pylori eradication has been shown to reduce duodenal ulcer recurrence risk.
Use: Eradication of H pylori infection in patients with active or a history (e.g., within 5 years) of duodenal ulcer infection and/or disease
Renal Dose Adjustments
Mild to moderate renal dysfunction: Data not available
Severe renal dysfunction: Contraindicated
Liver Dose Adjustments
Mild to moderate liver dysfunction (Child-Pugh A and B): Use with caution; monitoring is recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.
-Hypersensitivity to any/all of the active components (including other nitroimidazole derivatives) or the ingredients
-Patients taking methoxyflurane concurrently
-Patients who consumed alcoholic beverages at least 3 days during/after treatment
-Severe renal dysfunction
-Use in pregnancy
-Use of disulfiram within the last 2 weeks
US BOXED WARNINGS:
POTENTIAL FOR CARCINOGENICITY:
-Metronidazole has been shown to be carcinogenic in mice and rats.
-It is unknown whether metronidazole is associated with carcinogenicity in humans.
Safety and efficacy have not been established in pediatric patients.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be given with a full glass of water (e.g., 8 ounces), especially the bedtime dose.
-If a dose is missed, patients should continue the normal dosing schedule; patients should not take double doses.
-Limitation of use: This drug should be used only to treat infections that are proven/strongly suspected to be caused by susceptible bacteria.
-DERMATOLOGIC: Erythema/photosensitivity, signs/symptoms of cutaneous reactions
-HEMATOLOGIC: Initial and post-treatment total and differential leukocyte counts, especially in patients with evidence/history of blood dyscrasias
-OCULAR: Ophthalmologic evaluation in patients who develop visual disturbances
-Tell patients that it is important to complete the full regimen.
-Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, abnormal neurological effects, photosensitivity, or other cutaneous reactions occur.
-Patients should be told to avoid unprotected exposure to sunlight/UV light during treatment.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
More about bismuth subcitrate potassium / metronidazole / tetracycline
- Side effects
- Drug interactions
- During pregnancy
- Reviews (242)
- En español
- Drug class: H. pylori eradication agents
- Drug Information
- Bismuth subcitrate, metronidazole, and tetracycline (Advanced Reading)
- Bismuth Subcitrate, Metronidazole, and Tetracycline
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.